Estimate of prevalent hyperuricemia by systemic inflammation response index: results from a rural Chinese population

ABSTRACT

Objectives

Hyperuricemia is a common metabolic disease that is intimately correlated with inflammation. Our study aimed to investigate the value of systemic inflammation response index as a novel inflammatory marker to estimate hyperuricemia in the rural Chinese population.

Methods

This cross-sectional study used the data of 8,095 Chinese men and women aged ≥35 years from the 2012–2013 Northeast China Rural Cardiovascular Health Study.

Results

The overall prevalence of hyperuricemia was 12.84%. After fully adjusting for potential confounders, each SD increase of SIRI in men and women caused a 21.4% and 37.0% additional risk, respectively, for hyperuricemia. Moreover, smooth curve fitting and subgroup analyses corroborated the linearity and robustness of this correlation. ROC analysis showed the ability of SIRI to estimate hyperuricemia was significantly improved in females (0.741 vs 0.745, P = 0.043), but not in males (0.710 vs 0.714, P = 0.105). The net reclassification improvement (NRI, 0.120 in men vs 0.166 in women) and integrated discrimination improvement (IDI, 0.002 in men vs 0.006 in women) showed a significant improvement for both genders.

Conclusions

Our present study suggests a linear and robust relationship between SIRI and prevalent hyperuricemia, which implicates the value of SIRI to optimize the risk stratification and prevention of hyperuricemia.

KEYWORDS:

• Hyperuricemia
• systemic inflammation response index
• Inflammation
• Chinese population

Declaration of interest

The authors declare no conflicts of interest. The contents of the paper and the opinions expressed within are those of the authors, and it was the decision of the authors to submit the manuscript for publication.

Reviewer disclosures

Peer reviewers on this manuscript have no relevant financial or other relationships to disclose.

Additional information

Funding

This study was funded by National Key R&D Program of China (Grant #2017YFC1307600), the National Key Research and Development Program from the Ministry of Science and Technology of China (Project Grant # 2018YFC1312400, Sub-project Grant # 2018YFC1312403), Liaoning science and technology project, Research and demonstration of hypertension diagnosis and treatment and optimization of process management in Liaoning Province community (Grant #2017107001), and Science and Technology Program of Shenyang, China (Grant #‪17-230-9-06‬). The funders provided financial support without interfering with the design and analysis of the study.